Cerebrolysin does not improve global functional performance of patients with aneurysmal subarachnoid haemorrhage
06 Nov 2020
byNatalia Reoutova
A prospective, randomized, double-blind, placebo-controlled, parallel-group pilot study shows that use of cerebrolysin in addition to standard-of-care management of aneurysmal subarachnoid haemorrhage (SAH) is well tolerated and feasible, but does not improve the 6-month global functional performance of patients.